Sarah O'Laughlin Kulik's articles Life Sciences FTC and DOJ Finalize 2023 Merger Pointers – Duane Morris Life Sciences Regulation At present, the Federal Commerce Fee (“FTC”) and Division of Justice (“DOJ”) (collectively, the “Companies”) collectively launched the 2023 Merger Pointers . The 2023 Merger Pointers define the “elements and frameworks the companies make the most of when reviewing mergers and acquisitions,” together with each horizontal and vertical transactions. The 2023 […] Written by Sarah O'Laughlin Kulik March 25, 2024March 25, 2024 Saving Bookmark this article Bookmarked Life Sciences Senator reiterates FTC warnings relating to inhaler patents in Orange E book – Duane Morris Life Sciences Regulation Senator Tammy Baldwin (D-WI) despatched letters this week to firms warning of improper Orange E book listings of patents for inhalers, following up on the FTC’s deal with potential anticompetitive hurt of improper listings. In accordance with Senator Baldwin’s letters, the recipients of the letters have been warned by the FTC […] Written by Sarah O'Laughlin Kulik March 21, 2024March 21, 2024 Saving Bookmark this article Bookmarked Life Sciences Federal Trade Commission Issues Notice Letters Regarding Allegedly Improper Orange Book Listings – Duane Morris Life Sciences Law On November 7, 2023, the Federal Trade Commission (“FTC”) announced that it had issued notice letters to 10 life sciences companies regarding 100 patents that the FTC contends are improperly listed in the Orange Book, the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations. The announcement comes of the heels of […] Written by Sarah O'Laughlin Kulik November 8, 2023November 8, 2023 Saving Bookmark this article Bookmarked
Life Sciences FTC and DOJ Finalize 2023 Merger Pointers – Duane Morris Life Sciences Regulation At present, the Federal Commerce Fee (“FTC”) and Division of Justice (“DOJ”) (collectively, the “Companies”) collectively launched the 2023 Merger Pointers . The 2023 Merger Pointers define the “elements and frameworks the companies make the most of when reviewing mergers and acquisitions,” together with each horizontal and vertical transactions. The 2023 […] Written by Sarah O'Laughlin Kulik March 25, 2024March 25, 2024 Saving Bookmark this article Bookmarked
Life Sciences Senator reiterates FTC warnings relating to inhaler patents in Orange E book – Duane Morris Life Sciences Regulation Senator Tammy Baldwin (D-WI) despatched letters this week to firms warning of improper Orange E book listings of patents for inhalers, following up on the FTC’s deal with potential anticompetitive hurt of improper listings. In accordance with Senator Baldwin’s letters, the recipients of the letters have been warned by the FTC […] Written by Sarah O'Laughlin Kulik March 21, 2024March 21, 2024 Saving Bookmark this article Bookmarked
Life Sciences Federal Trade Commission Issues Notice Letters Regarding Allegedly Improper Orange Book Listings – Duane Morris Life Sciences Law On November 7, 2023, the Federal Trade Commission (“FTC”) announced that it had issued notice letters to 10 life sciences companies regarding 100 patents that the FTC contends are improperly listed in the Orange Book, the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations. The announcement comes of the heels of […] Written by Sarah O'Laughlin Kulik November 8, 2023November 8, 2023 Saving Bookmark this article Bookmarked
